# Retatrutide price and NHS access in the UK

> No retatrutide price exists yet. Projected UK pricing based on the tirzepatide and semaglutide precedent, and current costs of authorised alternatives.

Canonical: https://yezz.co.uk/price-and-nhs-access · Last reviewed: 2026-09-11 · Author: Nick Johnson, Independent Prescription Pricing Analyst, Medstack Ltd

## Key facts
- No brand name and no price have been announced in any country — every number on a sales page or “price predictor” is invented.
- Precedent suggests a premium private launch at or above Mounjaro’s top-dose pricing, with pharmacy competition pulling prices down over 1–2 years.
- The NHS route is the slowest: MHRA authorisation, NICE appraisal, then phased commissioning — 2029 at the earliest.
- “Pre-order”, “reserve stock” and “founder pricing” offers are scams built on the fact that no real price exists.
- Authorised options today: Wegovy ≈£100–£170 and Mounjaro ≈£94–£230 per month, delivered, through verified pharmacies.

---
Yezz is an independent UK information site run by Medstack Ltd. It sells nothing and provides general information, not medical advice.
Cite as: Nick Johnson. "Retatrutide price and NHS access in the UK". Yezz, 2026-09-11. https://yezz.co.uk/price-and-nhs-access